OptiNose Inc
NASDAQ:OPTN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
OptiNose Inc
Total Receivables
OptiNose Inc
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
OptiNose Inc
NASDAQ:OPTN
|
Total Receivables
$14.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Receivables
$14.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Receivables
$14.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
Pfizer Inc
NYSE:PFE
|
Total Receivables
$15.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
Merck & Co Inc
NYSE:MRK
|
Total Receivables
$12.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Receivables
$10B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
See Also
What is OptiNose Inc's Total Receivables?
Total Receivables
14.2m
USD
Based on the financial report for Mar 31, 2024, OptiNose Inc's Total Receivables amounts to 14.2m USD.
What is OptiNose Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
19%
Over the last year, the Total Receivables growth was -16%. The average annual Total Receivables growth rates for OptiNose Inc have been -8% over the past three years , 19% over the past five years .